Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study

Documenti analoghi

• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  di: Yunwen Xu, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
  di: Giovanni Antonio Silverii, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
  di: Dario Giugliano, et al.
  Pubblicazione: (2025)
• Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
  di: Huilin Tang, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
  di: Yu Mi Kang, et al.
  Pubblicazione: (2025)